Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for eFFECTOR Therapeutics, Inc. (EFTR : NSDQ)
 
 • Company Description   
eFFECTOR Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as STRIs. eFFECTOR Therapeutics Inc., formerly known as Locust Walk Acquisition Corp., is based in SAN DIEGO.

Number of Employees: 13

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.71 Daily Weekly Monthly
20 Day Moving Average: 22,860 shares
Shares Outstanding: 41.39 (millions)
Market Capitalization: $70.78 (millions)
Beta: 0.80
52 Week High: $40.42
52 Week Low: $1.63
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -48.49% -43.60%
12 Week -65.46% -61.17%
Year To Date -79.35% -74.77%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
142 North Cedros Avenue Suite B
-
Solana Beach,CA 92075
USA
ph: 858-925-8215
fax: -
None http://effector.com
 
 • General Corporate Information   
Officers
Stephen Worland - Chief Executive Officer and President
Brian M. Gallagher - Board Chair and Director
Elizabeth P. Bhatt - Chief Financial Officer
Chris Ehrlich - Director
Kristen Harrington-Smith - Director

Peer Information
eFFECTOR Therapeutics, Inc. (CORR.)
eFFECTOR Therapeutics, Inc. (RSPI)
eFFECTOR Therapeutics, Inc. (CGXP)
eFFECTOR Therapeutics, Inc. (BGEN)
eFFECTOR Therapeutics, Inc. (GTBP)
eFFECTOR Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 28202V108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/09/22
Share - Related Items
Shares Outstanding: 41.39
Most Recent Split Date: (:1)
Beta: 0.80
Market Capitalization: $70.78 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.18 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.51 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/09/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.80
Price/Cash Flow: 4.37
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -84.09%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -27.17%
ROE
03/31/22 - 263.41
12/31/21 - 474.57
09/30/21 - -
ROA
03/31/22 - 30.88
12/31/21 - 19.92
09/30/21 - -
Current Ratio
03/31/22 - 18.38
12/31/21 - 13.30
09/30/21 - 1.27
Quick Ratio
03/31/22 - 18.38
12/31/21 - 13.30
09/30/21 - 1.27
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - 3,448.37
12/31/21 - 1,104.76
09/30/21 - -
Book Value
03/31/22 - 0.61
12/31/21 - 0.43
09/30/21 - -0.19
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.75
12/31/21 - 1.09
09/30/21 - -
Debt-to-Capital
03/31/22 - 42.72
12/31/21 - 52.05
09/30/21 - -
 

Powered by Zacks Investment Research ©